Carbon monoxide and a change of heart

Louis M. Chu; Shazhad Shaefi; James D. Byrne; Rodrigo W. Alves de Souza; Leo E. Otterbein

doi:10.1016/j.redox.2021.102183

Back

Journal article

Open access

Peer reviewed

Carbon monoxide and a change of heart

Louis M. Chu, Shazhad Shaefi, James D. Byrne, Rodrigo W. Alves de Souza and Leo E. Otterbein

Redox biology, Vol.48, pp.102183-102183

12/01/2021

DOI: 10.1016/j.redox.2021.102183

PMCID: PMC8710986

PMID: 34764047

Files and links (1)

url

https://doi.org/10.1016/j.redox.2021.102183View

Published (Version of record) Open Access

Abstract

The relationship between carbon monoxide and the heart has been extensively studied in both clinical and preclinical settings. The Food and Drug Administration (FDA) is keenly focused on the ill effects of carbon monoxide on the heart when presented with proposals for clinical trials to evaluate efficacy of this gasotransmitter in a various disease settings. This review provides an overview of the rationale that examines the actions of the FDA when considering clinical testing of CO, and contrast that with the continued accumulation of data that clearly show not only that CO can be used safely, but is potently cardioprotective in clinically relevant small and large animal models. Data emerging from Phase I and Phase II clinical trials argues against CO being dangerous to the heart and thus it needs to be redefined and evaluated as any other substance being proposed for use in humans. More than twenty years ago, the belief that CO could be used as a salutary molecule was ridiculed by experts in physiology and medicine. Like all agents designed for use in humans, careful pharmacology and safety are paramount, but continuing to hinder progress based on long-standing dogma in the absence of data is improper. Now, CO is being tested in multiple clinical trials using innovative delivery methods and has proven to be safe. The hope, based on compelling preclinical data, is that it will continue to be evaluated and ultimately approved as an effective therapeutic.

Biochemistry & Molecular Biology

Life Sciences & Biomedicine

Science & Technology

Details

Title: Subtitle: Carbon monoxide and a change of heart
Creators: Louis M. Chu - Beth Israel Deaconess Medical Center
Shazhad Shaefi - Beth Israel Deaconess Medical Center
James D. Byrne - University of Iowa
Rodrigo W. Alves de Souza - Beth Israel Deaconess Medical Center
Leo E. Otterbein - Beth Israel Deaconess Medical Center
Resource Type: Journal article
Publication Details: Redox biology, Vol.48, pp.102183-102183
DOI: 10.1016/j.redox.2021.102183
PMID: 34764047
PMCID: PMC8710986
NLM abbreviation: Redox Biol
ISSN: 2213-2317
eISSN: 2213-2317
Publisher: Elsevier
Number of pages: 8
Grant note: 19CDA34760244 / American Heart Association National Football League Players Association W81XWH-16-0464 / Department of Defense; United States Department of Defense R43GM125430; R01DK119202; K08GM134220 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
Language: English
Date published: 12/01/2021
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Radiation Oncology
Record Identifier: 9984274858102771

Metrics

20 Record Views

32 Times Cited - Web of Science